{
  "completed": true,
  "status": "completed_original_source_reconciliation",
  "provider_mode": "Authenticated Consensus Deep research connector; completed provider output retained privately; original-source access checked separately",
  "queries": [
    "https://consensus.app/search/for-an-exhaustive-primary-literature-review-suppor/ITFmNdOOQjKS8-DTEgyHgQ/"
  ],
  "query_record_note": "Exact provider question/response retained privately in its retrieval receipt.",
  "primary_comparison_count": 10,
  "primary_comparisons": [
    {
      "pmid": "16352683",
      "doi": "10.1210/jc.2005-1536",
      "source_type": "primary study report",
      "study_group": "PMID16352683",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "CJC-1295 trial design, endpoints and access depth",
      "result_comparison": "Consensus correctly identified two blinded placebo-controlled ascending-dose trials and GH/IGF-I outcomes. Its own grounding snippets are labeled Abstract, despite a broader claim of Methods/Results validation. The original abstract confirms hormone activity and short tolerability, not clinical recovery; no original full-body access is asserted for this paper.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/16352683/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-0-10-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "25331030",
      "doi": "10.1007/s00384-014-2030-8",
      "source_type": "primary study report",
      "study_group": "PMID25331030",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Ipamorelin clinical endpoint and translational boundary",
      "result_comparison": "Consensus correctly reports a primary-null postoperative-ileus trial. The original randomized report gives meal-tolerance medians of25.3 and32.6 hours with p=0.15 and no significant key or secondary efficacy differences. This tests intravenous single-agent postoperative care, not the healthy-adult CJC-ipamorelin stack. Nonsignificance is not equivalence.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/25331030/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-0-10-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "19386527",
      "doi": "10.1016/j.ghir.2009.03.001",
      "source_type": "primary study report",
      "study_group": "CJC-pulsatility-cohort",
      "access_depth": "full_text_partial",
      "consensus_aspect": "CJC report overlap and biomarkers",
      "result_comparison": "Original Methods explicitly identify eleven men as a subset of a previously described cohort and repeat prior GH/IGF-I measurement procedures. The later serum-proteomic Results add candidate markers and correlations, not an independent clinical recovery experiment. Counts therefore group this report with the CJC pulsatility cohort rather than treating it as a new causal line.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/19386527/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-30-40-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\body-presentation-receipts\\19386527-s1-p0-1-13.json",
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\body-presentation-receipts\\19386527-s2-p2-3-4.json"
      ]
    },
    {
      "pmid": "18981485",
      "doi": "10.7326/0003-4819-149-9-200811040-00003",
      "source_type": "primary study report",
      "study_group": "PMID18981485",
      "access_depth": "full_text_partial",
      "consensus_aspect": "GH-axis body composition versus function and power",
      "result_comparison": "The original MK-677 Methods define blinded randomized treatment and function tests including walking, stairs and chair rise, with primary power for fat-free mass and visceral fat. Original Results show GH/IGF-I and mass changes, no significant function change, and worsened glycemic measures. This independently strengthens the provider-described biomarker/function boundary while retaining the limitation that functional nulls were not adequately powered equivalence tests.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/18981485/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-50-51-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\body-presentation-receipts\\18981485-s1-p0-1-10-11-18-19.json",
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\body-presentation-receipts\\18981485-s2-p4-5-15-16-20-21.json"
      ]
    },
    {
      "pmid": "25038357",
      "doi": "10.1001/jama.2014.8334",
      "source_type": "primary study report",
      "study_group": "NCT01263717",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Tesamorelin indication and original endpoint hierarchy",
      "result_comparison": "Consensus used this trial as a rigorous indication-specific comparator. Original Methods verify HIV-related abdominal adiposity enrollment, blinded treatment, CT/MRS and metabolic monitoring; Results confirm visceral/liver-fat reduction and transient glucose or insulin-sensitivity signals. These endpoints do not demonstrate healthy-adult recovery or establish the net benefit of another secretagogue combination.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/25038357/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-10-20-10000.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\body-presentation-receipts\\25038357-s1-p1-2-4-6.json",
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\body-presentation-receipts\\25038357-s2-p3-4-5-12.json"
      ]
    },
    {
      "pmid": "42542926",
      "doi": "10.52312/jdrs.2026.2951",
      "source_type": "primary study report",
      "study_group": "PMID42542926",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Latest component-dismantling animal result",
      "result_comparison": "The provider summary relies heavily on reviews for healing-peptide boundaries. The examined2026 original adds a four-arm thirty-two-rat Achilles-repair experiment: TB-500 alone showed significant mechanical benefit, and BPC-157 plus TB-500 did not add benefit over components. It strengthens the need for direct combination testing while preserving species, surgical-model and molecular-identity limits; it does not test CJC-ipamorelin.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/42542926/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-40-51-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "21204297",
      "doi": "10.1002/dta.233",
      "source_type": "primary study report",
      "study_group": "PMID21204297",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Commercial label versus clinical formulation identity",
      "result_comparison": "Consensus highlights the DAC versus similarly named marketed formulation boundary. The original analytical report identifies a twenty-nine-amino-acid peptide in an unknown product marketed as CJC-1295. Identity in that sample does not establish equivalence to the albumin-binding clinical formulation or market-wide safety and purity.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/21204297/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-30-40-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "10496658",
      "doi": "10.1023/a:1018955126402",
      "source_type": "primary study report",
      "study_group": "PMID10496658",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Human ipamorelin target engagement",
      "result_comparison": "Original human dose-escalation PK/PD confirms a GH episode after intravenous ipamorelin. This supports the biological rationale retained in the review, but it is neither an injected-combination clinical efficacy trial nor a chronic recovery-safety test. Provider included counts and research-gap matrix cells are not used as numbers of direct human efficacy trials.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/10496658/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-0-10-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "20439575",
      "doi": "10.7326/0003-4819-152-9-201005040-00007",
      "source_type": "primary study report",
      "study_group": "PMID20439575",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Positive sprint result and fluid interpretation",
      "result_comparison": "Consensus correctly notes a short-lived sprint effect and extracellular-water-driven lean-mass gain. The original blinded96-athlete trial reports a3.9percent GH-associated sprint increase, no significant other performance changes and loss of the sprint effect after washout. This positive is retained rather than cherry-picking only null GH comparators; it is a different hormone exposure and endpoint from exact-stack recovery.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/20439575/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-51-56-10000.json"
      ],
      "body_receipts": []
    },
    {
      "pmid": "10477776",
      "doi": "10.1056/NEJM199909093411102",
      "source_type": "primary study report",
      "study_group": "PMID10477776",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "Critical-illness safety boundary",
      "result_comparison": "The original two randomized high-dose GH trials show increased mortality in prolonged critical illness. This serious harm must remain bounded to its measured population and exposure; it cannot become an asserted CJC-ipamorelin mortality rate in healthy adults.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/10477776/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\examinations\\original-51-56-10000.json"
      ],
      "body_receipts": []
    }
  ],
  "grade_changed": false,
  "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.",
  "raw_receipts": [
    {
      "path": "deliverables\\hsef_v53_traffic_ranks_06_10_2026-10-13\\peptide-stacks-recovery\\consensus-provider-checkpoint-1551-private.json",
      "sha256": "dd476771ded70863f0c0690e923bf411f3951dad26c55463e8bf4a03f3ebd5cd"
    }
  ],
  "independent_blinded_audit": false,
  "cutoff": "2026-10-13",
  "completed_utc": "2026-10-13T16:38:31.829865+00:00",
  "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them."
}